A Study of IMC-1 In Patients With Fibromyalgia

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Innovative Med Concepts, LLC

Criteria

Inclusion Criteria:

• Diagnosis of fibromyalgia

• English speaker

Exclusion Criteria:

• Rheumatologic diseases

• Bipolar disease, OCD, severe anxiety, schizophrenia

• Systemic infection, severe cardiac disease, chronic steroid usage

• chronic opioid usage